A Study of Intravitreal Injections of 2.0mg Ranibizumab in Subjects With Chronic Fluid On OCT Post Multiple Injections With Ranibizumab (Super-dose Anti-VEgf SAVE Trial)
Stopped The last remaining subject withdrew consent because the collaborator Genentech stopped supplying study drug.
Conditions
- Age Related Macular Degeneration
- Choroidal Neovascular Membrane
- Subfoveal Neovascular Age-Related Macular Degeneration
- Macular Degeneration
- Wet Age-Related Macular Degeneration
Interventions
Sponsor
David M. Brown, M.D.
Collaborators